{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:49:50Z","timestamp":1792039790152,"version":"4.4.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2025\/SKK15\/USM\/02\/1"],"award-info":[{"award-number":["FRGS\/1\/2025\/SKK15\/USM\/02\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00044-026-03577-8","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:31:36Z","timestamp":1779773496000},"page":"1905-1929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small Molecule Insulin Sensitisers: New Leads and Targets for Next-Generation Insulin Sensitising Strategies"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-3794","authenticated-orcid":false,"given":"Chong-Yew","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"3577_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","volume":"14","author":"I Genitsaridi","year":"2026","unstructured":"Genitsaridi I, Salpea P, Salim A, Sajjadi SF, Tomic D, James S, et al. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 2026;14:149\u201356. https:\/\/doi.org\/10.1016\/S2213-8587(25)00299-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3577_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7:216. https:\/\/doi.org\/10.1038\/s41392-022-01073-0.","journal-title":"Signal Transduct Target Ther"},{"key":"3577_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10753-021-01559-z","volume":"45","author":"L Al-Mansoori","year":"2022","unstructured":"Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA. Role of Inflammatory Cytokines, Growth Factors and Adipokines in Adipogenesis and Insulin Resistance. Inflammation. 2022;45:31\u201344. https:\/\/doi.org\/10.1007\/s10753-021-01559-z.","journal-title":"Inflammation"},{"key":"3577_CR4","doi-asserted-by":"publisher","first-page":"1692742","DOI":"10.3389\/fimmu.2025.1692742","volume":"16","author":"S Saadati","year":"2025","unstructured":"Saadati S, Godini R, Reddy A, Teede H, Mousa A. Metabolic crossroads in insulin resistance: exploring lipid dysregulation and inflammation. Front Immunol. 2025;16:1692742. https:\/\/doi.org\/10.3389\/fimmu.2025.1692742.","journal-title":"Front Immunol"},{"key":"3577_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/kjm2.12800","volume":"40","author":"K Chong","year":"2024","unstructured":"Chong K, Chang JK, Chuang LM. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J Med Sci. 2024;40:212\u201320. https:\/\/doi.org\/10.1002\/kjm2.12800.","journal-title":"Kaohsiung J Med Sci"},{"key":"3577_CR6","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.jcte.2024.100335","volume":"35","author":"I Hasan","year":"2024","unstructured":"Hasan I, Rashid T, Jaikaransingh V, Heilig C, Abdel-Rahman EM, Awad AS. SGLT2 inhibitors: Beyond glycemic control. J Clin Transl Endocrinol. 2024;35:100335. https:\/\/doi.org\/10.1016\/j.jcte.2024.100335.","journal-title":"J Clin Transl Endocrinol"},{"key":"3577_CR7","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103363.","journal-title":"EClinicalMedicine"},{"key":"3577_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","volume":"23","author":"B Cariou","year":"2012","unstructured":"Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPAR\u03b3 agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205\u201315. https:\/\/doi.org\/10.1016\/j.tem.2012.03.001.","journal-title":"Trends Endocrinol Metab"},{"key":"3577_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3389\/fphar.2018.01093","volume":"9","author":"PR Devchand","year":"2018","unstructured":"Devchand PR, Liu T, Altman RB, et al. The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond. Front Pharmacol. 2018;9:1093. https:\/\/doi.org\/10.3389\/fphar.2018.01093.","journal-title":"Front Pharmacol"},{"key":"3577_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2165\/00002018-200730090-00002","volume":"30","author":"J Karalliedde","year":"2007","unstructured":"Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 2007;30:741\u201353. https:\/\/doi.org\/10.2165\/00002018-200730090-00002.","journal-title":"Drug Saf"},{"key":"3577_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11914-010-0027-y","volume":"8","author":"B Lecka-Czernik","year":"2010","unstructured":"Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8:178\u201384. https:\/\/doi.org\/10.1007\/s11914-010-0027-y.","journal-title":"Curr Osteoporos Rep"},{"key":"3577_CR12","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","volume":"121","author":"S Kaul","year":"2010","unstructured":"Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121:1868\u201377. https:\/\/doi.org\/10.1161\/CIR.0b013e3181d34114.","journal-title":"Circulation"},{"key":"3577_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA. 2015;314:265\u201377. https:\/\/doi.org\/10.1001\/jama.2015.7996.","journal-title":"JAMA"},{"key":"3577_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20:573\u201391. https:\/\/doi.org\/10.1016\/j.cmet.2014.08.005.","journal-title":"Cell Metab"},{"key":"3577_CR15","doi-asserted-by":"publisher","unstructured":"Saltiel AR. Insulin signaling in health and disease. J Clin Invest 2021131: e142241. https:\/\/doi.org\/10.1172\/JCI142241","DOI":"10.1172\/JCI142241"},{"key":"3577_CR16","doi-asserted-by":"publisher","first-page":"1226655","DOI":"10.3389\/fendo.2023.1226655","volume":"14","author":"TKC Le","year":"2023","unstructured":"Le TKC, Dao XD. Insulin signaling and its application. Front Endocrinol. 2023;14:1226655. https:\/\/doi.org\/10.3389\/fendo.2023.1226655.","journal-title":"Front Endocrinol"},{"key":"3577_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/cmdc.201600182","volume":"11","author":"A Daina","year":"2016","unstructured":"Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem. 2016;11:1117\u201321. https:\/\/doi.org\/10.1002\/cmdc.201600182.","journal-title":"ChemMedChem"},{"key":"3577_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi JH, Banks AS, Estall JL, Kajimura S, Bostr\u00f6m P, Laznik D, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature. 2010;466:451\u20136. https:\/\/doi.org\/10.1038\/nature09291.","journal-title":"Nature"},{"key":"3577_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature10383","volume":"477","author":"JH Choi","year":"2011","unstructured":"Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, et al. Antidiabetic actions of a non-agonist PPAR\u03b3 ligand blocking Cdk5-mediated phosphorylation. Nature. 2011;477:477\u201381. https:\/\/doi.org\/10.1038\/nature10383.","journal-title":"Nature"},{"key":"3577_CR20","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1101\/gad.249367.114","volume":"28","author":"JH Choi","year":"2014","unstructured":"Choi JH, Choi SS, Kim ES, Jedrychowski MP, Yang YR, Jang HJ, et al. Thrap3 docks on phosphoserine 273 of PPAR\u03b3 and controls diabetic gene programming. Genes Dev. 2014;28:2361\u20139. https:\/\/doi.org\/10.1101\/gad.249367.114.","journal-title":"Genes Dev"},{"key":"3577_CR21","doi-asserted-by":"publisher","first-page":"e102102","DOI":"10.1371\/journal.pone.0102102","volume":"9","author":"Y Ming","year":"2014","unstructured":"Ming Y, Hu X, Song Y, Liu Z, Li J, Gao R, et al. CMHX008, a novel peroxisome proliferator-activated receptor \u03b3 partial agonist, enhances insulin sensitivity in vitro and in vivo. PLoS ONE. 2014;9:e102102. https:\/\/doi.org\/10.1371\/journal.pone.0102102.","journal-title":"PLoS ONE"},{"key":"3577_CR22","doi-asserted-by":"publisher","first-page":"26618","DOI":"10.1074\/jbc.M114.566794","volume":"289","author":"SS Choi","year":"2014","unstructured":"Choi SS, Kim ES, Koh M, Lee SJ, Lim D, Yang YR, et al. A novel non-agonist peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligand UHC1 blocks PPAR\u03b3 phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity. J Biol Chem. 2014;289:26618\u201329. https:\/\/doi.org\/10.1074\/jbc.M114.566794.","journal-title":"J Biol Chem"},{"key":"3577_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbagen.2014.09.027","volume":"1850","author":"X Xie","year":"2015","unstructured":"Xie X, Zhou X, Chen W, Long L, Li W, Yang X, et al. L312, a novel PPAR\u03b3 ligand with potent anti-diabetic activity by selective regulation. Biochim Biophys Acta. 2015;1850:62\u201372. https:\/\/doi.org\/10.1016\/j.bbagen.2014.09.027.","journal-title":"Biochim Biophys Acta"},{"key":"3577_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.bmc.2012.11.058","volume":"21","author":"JP Taygerly","year":"2013","unstructured":"Taygerly JP, McGee LR, Rubenstein SM, Houze JB, Cushing TD, Li Y, et al. Discovery of INT131: a selective PPAR\u03b3 modulator that enhances insulin sensitivity. Bioorg Med Chem. 2013;21:979\u201392. https:\/\/doi.org\/10.1016\/j.bmc.2012.11.058.","journal-title":"Bioorg Med Chem"},{"key":"3577_CR25","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1007\/s00044-013-0814-y","volume":"23","author":"N Deka","year":"2014","unstructured":"Deka N, Uravane M, Anthony J, Bhumra SK, Nair A, Rao C, et al. Design and synthesis of non-TZD peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) modulator. Med Chem Res. 2014;23:2150\u20139. https:\/\/doi.org\/10.1007\/s00044-013-0814-y.","journal-title":"Med Chem Res"},{"key":"3577_CR26","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.2337\/dc13-2480","volume":"37","author":"AM DePaoli","year":"2014","unstructured":"DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL, INT131-007 Study Group. Can a selective PPAR\u03b3 modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care. 2014;37:1918\u201323. https:\/\/doi.org\/10.2337\/dc13-2480.","journal-title":"Diabetes Care"},{"key":"3577_CR27","doi-asserted-by":"publisher","first-page":"101363","DOI":"10.1016\/j.molmet.2021.101363","volume":"54","author":"D Wu","year":"2021","unstructured":"Wu D, Eeda V, Undi RB, Mann S, Stout M, Lim HY, et al. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice. Mol Metab. 2021;54:101363. https:\/\/doi.org\/10.1016\/j.molmet.2021.101363.","journal-title":"Mol Metab"},{"key":"3577_CR28","doi-asserted-by":"publisher","first-page":"bqaa017","DOI":"10.1210\/endocr\/bqaa017","volume":"161","author":"P Sangwung","year":"2020","unstructured":"Sangwung P, Petersen KF, Shulman GI, Knowles JW. Mitochondrial Dysfunction, Insulin Resistance, and Potential Genetic Implications. Endocrinology. 2020;161:bqaa017. https:\/\/doi.org\/10.1210\/endocr\/bqaa017.","journal-title":"Endocrinology"},{"key":"3577_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/biom15020223","volume":"15","author":"H Politte","year":"2025","unstructured":"Politte H, Maram L, Elgendy B. Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications. Biomolecules. 2025;15:223. https:\/\/doi.org\/10.3390\/biom15020223.","journal-title":"Biomolecules"},{"key":"3577_CR30","doi-asserted-by":"publisher","first-page":"E33","DOI":"10.1152\/ajpendo.00074.2022","volume":"323","author":"NKH Yiew","year":"2022","unstructured":"Yiew NKH, Finck BN. The mitochondrial pyruvate carrier at the crossroads of intermediary metabolism. Am J Physiol Endocrinol Metab. 2022;323:E33\u201352. https:\/\/doi.org\/10.1152\/ajpendo.00074.2022.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3577_CR31","doi-asserted-by":"publisher","first-page":"e14016","DOI":"10.1111\/apha.14016","volume":"238","author":"S Tavoulari","year":"2023","unstructured":"Tavoulari S, Sichrovsky M, Kunji ERS. Fifty years of the mitochondrial pyruvate carrier: New insights into its structure, function, and inhibition. Acta Physiol. 2023;238:e14016. https:\/\/doi.org\/10.1111\/apha.14016.","journal-title":"Acta Physiol"},{"key":"3577_CR32","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1073\/pnas","volume":"110","author":"AS Divakaruni","year":"2013","unstructured":"Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan S, Loviscach M, et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A. 2013;110:5422\u20137. https:\/\/doi.org\/10.1073\/pnas.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3577_CR33","doi-asserted-by":"publisher","first-page":"e61551","DOI":"10.1371\/journal.pone.0061551","volume":"8","author":"JR Colca","year":"2013","unstructured":"Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE. 2013;8:e61551. https:\/\/doi.org\/10.1371\/journal.pone.0061551.","journal-title":"PLoS ONE"},{"key":"3577_CR34","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/acsmedchemlett.0c00052","volume":"11","author":"S DeWitt","year":"2020","unstructured":"DeWitt S, Czarnik AW, Jacques V. Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting Racemates. ACS Med Chem Lett. 2020;11:1789\u201392. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00052","journal-title":"ACS Med Chem Lett"},{"key":"3577_CR35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/clpt.2013.10","volume":"93","author":"JR Colca","year":"2013","unstructured":"Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin Pharmacol Ther. 2013;93:352\u20139. https:\/\/doi.org\/10.1038\/clpt.2013.10.","journal-title":"Clin Pharmacol Ther"},{"key":"3577_CR36","doi-asserted-by":"publisher","first-page":"174627","DOI":"10.1016\/j.ejphar.2021.174627","volume":"913","author":"M Touaibia","year":"2021","unstructured":"Touaibia M, St-Coeur PD, Duff P, Faye DC, Pichaud N. 5-Benzylidene, 5-benzyl, and 3-benzylthiazolidine-2,4-diones as potential inhibitors of the mitochondrial pyruvate carrier: Effects on mitochondrial functions and survival in Drosophila melanogaster. Eur J Pharmacol. 2021;913:174627. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174627.","journal-title":"Eur J Pharmacol"},{"key":"3577_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1042\/BJ20141171","volume":"466","author":"KS McCommis","year":"2015","unstructured":"McCommis KS, Finck BN. 2015. Mitochondrial pyruvate transport: a historical perspective and future research directions. Biochem J. 2015;466:443\u2013454.","journal-title":"Biochem J"},{"key":"3577_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell JB, Nissink JWM. Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations. ACS Chem Biol. 2018;13:36\u201344. https:\/\/doi.org\/10.1021\/acschembio.7b00903.","journal-title":"ACS Chem Biol"},{"key":"3577_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/biomedicines10020365","volume":"10","author":"L Hegazy","year":"2022","unstructured":"Hegazy L, Gill LE, Pyles KD, Kaiho C, Kchouk S, Finck BN, et al. Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening. Biomedicines. 2022;10:365. https:\/\/doi.org\/10.3390\/biomedicines10020365.","journal-title":"Biomedicines"},{"key":"3577_CR40","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.freeradbiomed.2023.10.148","volume":"203","author":"MF Caggiano","year":"2023","unstructured":"Caggiano MF, Charles R, Prysyazhna O, Eaton P. UK-5099 does not inhibit the mitochondrial pyruvate carrier through irreversible adduction to cysteine 54 in MPC2. Free Rad Biol Med. 2023;203:S66. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.10.148.","journal-title":"Free Rad Biol Med"},{"key":"3577_CR41","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41586-025-08667-y","volume":"641","author":"Z He","year":"2025","unstructured":"He Z, Zhang J, Xu Y, Fine EJ, Suomivuori CM, Dror RO, et al. Structure of mitochondrial pyruvate carrier and its inhibition mechanism. Nature. 2025;641:250\u20137. https:\/\/doi.org\/10.1038\/s41586-025-08667-y.","journal-title":"Nature"},{"key":"3577_CR42","doi-asserted-by":"publisher","first-page":"eadw1489","DOI":"10.1126\/sciadv.adw1489","volume":"11","author":"M Sichrovsky","year":"2025","unstructured":"Sichrovsky M, Lacabanne D, Ruprecht JJ, Rana JJ, Stanik K, Dionysopoulou M, et al. Molecular basis of pyruvate transport and inhibition of the human mitochondrial pyruvate carrier. Sci Adv. 2025;11:eadw1489. https:\/\/doi.org\/10.1126\/sciadv.adw1489.","journal-title":"Sci Adv"},{"key":"3577_CR43","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1089\/ars.2018.7502","volume":"30","author":"R Mittler","year":"2019","unstructured":"Mittler R, Darash-Yahana M, Sohn YS, Bai F, Song L, Cabantchik IZ, et al. NEET Proteins: A New Link Between Iron Metabolism, Reactive Oxygen Species, and Cancer. Antioxid Redox Signal. 2019;30:1083\u201395. https:\/\/doi.org\/10.1089\/ars.2018.7502.","journal-title":"Antioxid Redox Signal"},{"key":"3577_CR44","doi-asserted-by":"publisher","first-page":"118805","DOI":"10.1016\/j.bbamcr.2020.118805","volume":"1867","author":"R Nechushtai","year":"2020","unstructured":"Nechushtai R, Karmi O, Zuo K, Marjault HB, Darash-Yahana M, Sohn YS, et al. The balancing act of NEET proteins: Iron, ROS, calcium and metabolism. Biochim Biophys Acta Mol Cell Res. 2020;1867:118805. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118805.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"3577_CR45","doi-asserted-by":"publisher","first-page":"13047","DOI":"10.1073\/pnas.1109986108","volume":"108","author":"JA Zuris","year":"2011","unstructured":"Zuris JA, Harir Y, Conlan AR, Shvartsman M, Michaeli D, Tamir S, et al. Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor protein. Proc Natl Acad Sci USA. 2011;108:13047\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3577_CR46","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1016\/j.bmcl.2016.09.009","volume":"26","author":"WJ Geldenhuys","year":"2016","unstructured":"Geldenhuys WJ, Yonutas HM, Morris DL, Sullivan PG, Darvesh AS, Leeper TC. Identification of small molecules that bind to the mitochondrial protein mitoNEET. Bioorg Med Chem Lett. 2016;26:5350\u20133. https:\/\/doi.org\/10.1016\/j.bmcl.2016.09.009.","journal-title":"Bioorg Med Chem Lett"},{"key":"3577_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1124\/jpet.114.220673","volume":"352","author":"T Takahashi","year":"2015","unstructured":"Takahashi T, Yamamoto M, Amikura K, Kato K, Serizawa T, Serizawa K, et al. A novel MitoNEET ligand, TT01001, improves diabetes and ameliorates mitochondrial function in db\/db mice. J Pharmacol Exp Ther. 2015;352:338\u201345. https:\/\/doi.org\/10.1124\/jpet.114.220673.","journal-title":"J Pharmacol Exp Ther"},{"key":"3577_CR48","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s42003-022-03393-x","volume":"5","author":"HB Marjault","year":"2022","unstructured":"Marjault HB, Karmi O, Zuo K, Michaeli D, Eisenberg-Domovich Y, Rossetti G, et al. An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters. Commun Biol. 2022;5:437. https:\/\/doi.org\/10.1038\/s42003-022-03393-x.","journal-title":"Commun Biol"},{"key":"3577_CR49","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s41467-020-16298-2","volume":"11","author":"SJ Alexopoulos","year":"2020","unstructured":"Alexopoulos SJ, Chen SY, Brandon AE, Salamoun JM, Byrne FL, Garcia CJ, Beretta M, Olzomer EM, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun. 2020;11:2397. https:\/\/doi.org\/10.1038\/s41467-020-16298-2.","journal-title":"Nat Commun"},{"key":"3577_CR50","doi-asserted-by":"publisher","first-page":"154724","DOI":"10.1016\/j.metabol.2021.154724","volume":"117","author":"SY Chen","year":"2021","unstructured":"Chen SY, Beretta M, Alexopoulos SJ, Shah DP, Olzomer EM, Hargett SR, et al. Mitochondrial uncoupler SHC517 reverses obesity in mice without affecting food intake. Metabolism. 2021;117:154724. https:\/\/doi.org\/10.1016\/j.metabol.2021.154724.","journal-title":"Metabolism"},{"key":"3577_CR51","doi-asserted-by":"publisher","first-page":"117035","DOI":"10.1016\/j.ejmech.2024.117035","volume":"281","author":"A Kousaxidis","year":"2025","unstructured":"Kousaxidis A, Paoli P, Kovacikova L, Genovese M, Santi A, Stefek M, Petrou A, Nicolaou I. Rational design and synthesis of novel N-benzylindole-based epalrestat analogs as selective aldose reductase inhibitors: An unexpected discovery of a new glucose-lowering agent (AK-4) acting as a mitochondrial uncoupler. Eur J Med Chem. 2025;281:117035. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117035.","journal-title":"Eur J Med Chem"},{"key":"3577_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121\u201335. https:\/\/doi.org\/10.1038\/nrm.2017.95.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3577_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","volume":"24","author":"GR Steinberg","year":"2023","unstructured":"Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24:255\u201372. https:\/\/doi.org\/10.1038\/s41580-022-00547-x.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"3577_CR54","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577\u201385. https:\/\/doi.org\/10.1007\/s00125-017-4342-z.","journal-title":"Diabetologia"},{"key":"3577_CR55","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/dom.14277","volume":"23","author":"S Hallakou-Bozec","year":"2021","unstructured":"Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, et al. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23:664\u201373. https:\/\/doi.org\/10.1111\/dom.14277.","journal-title":"Diabetes Obes Metab"},{"key":"3577_CR56","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2015.09.032","volume":"243","author":"A Pirillo","year":"2015","unstructured":"Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis. 2015;243:449\u201361. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.09.032.","journal-title":"Atherosclerosis"},{"key":"3577_CR57","doi-asserted-by":"publisher","unstructured":"Ji J, Ma M, Ma Y, Cheng Z, Gan S, Yuan G, et al. Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2025;8(e2462185). https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.62185.","DOI":"10.1001\/jamanetworkopen.2024.62185"},{"key":"3577_CR58","doi-asserted-by":"publisher","first-page":"e18835","DOI":"10.1590\/s2175-97902020000318835","volume":"59","author":"MS Filli","year":"2023","unstructured":"Filli MS, Ibrahim AA, Aquib M, Boakye-Yiadom KO, Kesse S, Farooq MA, et al. Synthetic Berberine Derivatives As Potential New Drugs. Braz J Pharm Sci. 2023;59:e18835. https:\/\/doi.org\/10.1590\/s2175-97902020000318835.","journal-title":"Braz J Pharm Sci"},{"key":"3577_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bcp.2018.01.049","volume":"153","author":"S Olivier","year":"2018","unstructured":"Olivier S, Foretz M, Viollet B. Promise and challenges for direct small molecule AMPK activators. Biochem Pharmacol. 2018;153:147\u201358. https:\/\/doi.org\/10.1016\/j.bcp.2018.01.049.","journal-title":"Biochem Pharmacol"},{"key":"3577_CR60","doi-asserted-by":"publisher","first-page":"102042","DOI":"10.1016\/j.molmet.2024.102042","volume":"90","author":"WJ Smiles","year":"2024","unstructured":"Smiles WJ, Ovens AJ, Oakhill JS, Kofler B. The metabolic sensor AMPK: Twelve enzymes in one. Mol Metab. 2024;90:102042. https:\/\/doi.org\/10.1016\/j.molmet.2024.102042.","journal-title":"Mol Metab"},{"key":"3577_CR61","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1038\/ncomms4017","volume":"4","author":"B Xiao","year":"2013","unstructured":"Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017. https:\/\/doi.org\/10.1038\/ncomms4017.","journal-title":"Nat Commun"},{"key":"3577_CR62","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","volume":"18","author":"GR Steinberg","year":"2019","unstructured":"Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov. 2019;18:527\u201351. https:\/\/doi.org\/10.1038\/s41573-019-0019-2.","journal-title":"Nat Rev Drug Discov"},{"key":"3577_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cmet.2006.05.005","volume":"3","author":"B Cool","year":"2006","unstructured":"Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006;3:403\u201316. https:\/\/doi.org\/10.1016\/j.cmet.2006.05.005.","journal-title":"Cell Metab"},{"key":"3577_CR64","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.chembiol.2014.03.006","volume":"21","author":"JW Scott","year":"2014","unstructured":"Scott JW, Ling N, Issa SM, Dite TA, O\u2019Brien MT, Chen ZP, et al. Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. Chem Biol. 2014;21:619\u201327. https:\/\/doi.org\/10.1016\/j.chembiol.2014.03.006.","journal-title":"Chem Biol"},{"key":"3577_CR65","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1021\/acs.jmedchem.7b01641","volume":"61","author":"DJ Edmonds","year":"2018","unstructured":"Edmonds DJ, Kung DW, Kalgutkar AS, Filipski KJ, Ebner DC, Cabral S, et al. Optimization of Metabolic and Renal Clearance in a Series of Indole Acid Direct Activators of 5\u2019-Adenosine Monophosphate-Activated Protein Kinase (AMPK). J Med Chem. 2018;61:2372\u201383. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01641.","journal-title":"J Med Chem"},{"key":"3577_CR66","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.cmet.2017.04.010","volume":"25","author":"EC Cokorinos","year":"2017","unstructured":"Cokorinos EC, Delmore J, Reyes AR, Albuquerque B, Kj\u00f8bsted R, J\u00f8rgensen NO, et al. Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice. Cell Metab. 2017;25:1147\u2013e115910. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.010.","journal-title":"Cell Metab"},{"key":"3577_CR67","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.chembiol.2018.03.008","volume":"25","author":"KRW Ngoei","year":"2018","unstructured":"Ngoei KRW, Langendorf CG, Ling NXY, Hoque A, Varghese S, Camerino MA, et al. Structural Determinants for Small-Molecule Activation of Skeletal Muscle AMPK \u03b12\u03b22\u03b31 by the Glucose Importagog SC4. Cell Chem Biol. 2018;25:728\u2013e7379. https:\/\/doi.org\/10.1016\/j.chembiol.2018.03.008","journal-title":"Cell Chem Biol"},{"key":"3577_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/acsmedchemlett.7b00417","volume":"9","author":"D Feng","year":"2017","unstructured":"Feng D, Biftu T, Romero FA, Kekec A, Dropinski J, Kassick A, et al. Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase. ACS Med Chem Lett. 2017;9:39\u201344. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00417.","journal-title":"ACS Med Chem Lett"},{"issue":"6350","key":"3577_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1126\/science.aah5582","volume":"357","author":"RW Myers","year":"2017","unstructured":"Myers RW, Guan HP, Ehrhart J, Petrov A, Prahalada S, Tozzo E, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science. 2017;357(6350):507\u201311. https:\/\/doi.org\/10.1126\/science.aah5582.","journal-title":"Science"},{"key":"3577_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4093\/dmj.2013.37.1.1","volume":"37","author":"HM O\u2019Neill","year":"2013","unstructured":"O\u2019Neill HM. AMPK and Exercise: Glucose Uptake and Insulin Sensitivity. Diabetes Metab J. 2013;37:1\u201321. https:\/\/doi.org\/10.4093\/dmj.2013.37.1.1.","journal-title":"Diabetes Metab J"},{"key":"3577_CR71","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1042\/BCJ20220067","volume":"479","author":"AJ Ovens","year":"2022","unstructured":"Ovens AJ, Gee YS, Ling NXY, Yu D, Hardee JP, Chung JD, et al. Structure-function analysis of the AMPK activator SC4 and identification of a potent pan AMPK activator. Biochem J. 2022;479:1181\u2013204. https:\/\/doi.org\/10.1042\/BCJ20220067.","journal-title":"Biochem J"},{"key":"3577_CR72","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","volume":"6","author":"K Cusi","year":"2021","unstructured":"Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, et al. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Gastroenterol Hepatol. 2021;6:889\u2013902. https:\/\/doi.org\/10.1016\/S2468-1253(21)00300-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3577_CR73","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","volume":"55","author":"AT Turer","year":"2012","unstructured":"Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55:2319\u201326. https:\/\/doi.org\/10.1007\/s00125-012-2598-x.","journal-title":"Diabetologia"},{"key":"3577_CR74","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4093\/dmj.2015.39.5.363","volume":"39","author":"M Okada-Iwabu","year":"2015","unstructured":"Okada-Iwabu M, Iwabu M, Ueki K, Yamauchi T, Kadowaki T. Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity. Diabetes Metab J. 2015;39:363\u201372. https:\/\/doi.org\/10.4093\/dmj.2015.39.5.363.","journal-title":"Diabetes Metab J"},{"key":"3577_CR75","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature12656","volume":"503","author":"M Okada-Iwabu","year":"2013","unstructured":"Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503:493\u20139. https:\/\/doi.org\/10.1038\/nature12656.","journal-title":"Nature"},{"key":"3577_CR76","doi-asserted-by":"publisher","first-page":"E275","DOI":"10.1152\/ajpendo.00577.2014","volume":"309","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhao J, Li R, Lau WB, Yuan YX, Liang B, et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab. 2015;309:E275\u201382. https:\/\/doi.org\/10.1152\/ajpendo.00577.2014.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"3577_CR77","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/bph.15277","volume":"178","author":"W Qiu","year":"2021","unstructured":"Qiu W, Wu H, Hu Z, Wu X, Tu M, Fang F, et al. Identification and characterization of a novel adiponectin receptor agonist adipo anti-inflammation agonist and its anti-inflammatory effects in vitro and in vivo. Br J Pharmacol. 2021;178(2):280\u201397. https:\/\/doi.org\/10.1111\/bph.15277.","journal-title":"Br J Pharmacol"},{"key":"3577_CR78","doi-asserted-by":"publisher","first-page":"114800","DOI":"10.1016\/j.ejmech.2022.114800","volume":"244","author":"L Dai","year":"2022","unstructured":"Dai L, Wang Q, Wang P, Zhang S, Tai L, Xu X, et al. Discovery of novel AdipoRon analogues as potent anti-inflammatory agents against nonalcoholic steatohepatitis. Eur J Med Chem. 2022;244:114800. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114800.","journal-title":"Eur J Med Chem"},{"key":"3577_CR79","doi-asserted-by":"publisher","first-page":"112466","DOI":"10.1016\/j.ejmech.2020.112466","volume":"200","author":"G Sun","year":"2020","unstructured":"Sun G, You Y, Li H, Cheng Y, Qian M, Zhou X, et al. Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I. Eur J Med Chem. 2020;200:112466. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112466.","journal-title":"Eur J Med Chem"},{"key":"3577_CR80","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1039\/d3md00727h","volume":"15","author":"C Lin","year":"2024","unstructured":"Lin C, Sun G, Li Y. Identification of AdipoRon analogues as novel activators of AMPK for the treatment of type 2 diabetes. RSC Med Chem. 2024;15:2413\u201321. https:\/\/doi.org\/10.1039\/d3md00727h.","journal-title":"RSC Med Chem"},{"key":"3577_CR81","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.jlr.2021.100095","volume":"62","author":"T Onodera","year":"2021","unstructured":"Onodera T, Ghazvini Zadeh E, Xu P, Gordillo R, Guo Z, Joffin N, et al. PEGylated AdipoRon derivatives improve glucose and lipid metabolism under insulinopenic and high-fat diet conditions. J Lipid Res. 2021;62:100095. https:\/\/doi.org\/10.1016\/j.jlr.2021.100095.","journal-title":"J Lipid Res"},{"key":"3577_CR82","doi-asserted-by":"publisher","first-page":"114141","DOI":"10.1016\/j.biopha.2022.114141","volume":"158","author":"OK Ma","year":"2023","unstructured":"Ma OK, Ronsisvalle S, Basile L, Xiang AW, Tomasella C, et al. Identification of a novel adiponectin receptor and opioid receptor dual acting agonist as a potential treatment for diabetic neuropathy. Biomed Pharmacother. 2023;158:114141. https:\/\/doi.org\/10.1016\/j.biopha.2022.114141.","journal-title":"Biomed Pharmacother"},{"key":"3577_CR83","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41538-021-00114-2","volume":"5","author":"Y Lee","year":"2021","unstructured":"Lee Y, Nakano A, Nakamura S, Sakai K, Tanaka M, Sanematsu K, et al. In vitro and in silico characterization of adiponectin-receptor agonist dipeptides. NPJ Sci Food. 2021;5:29. https:\/\/doi.org\/10.1038\/s41538-021-00114-2.","journal-title":"NPJ Sci Food"},{"key":"3577_CR84","doi-asserted-by":"publisher","first-page":"7695","DOI":"10.1021\/acs.jafc.2c02115","volume":"70","author":"Y Lee","year":"2022","unstructured":"Lee Y, Nakano A, Nagasato Y, Ichinose T, Matsui T. In Vitro and in Silico Analyses of the Adiponectin Receptor Agonistic Action of Soybean Tripeptides. J Agric Food Chem. 2022;70:7695\u2013703. https:\/\/doi.org\/10.1021\/acs.jafc.2c02115.","journal-title":"J Agric Food Chem"},{"key":"3577_CR85","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1021\/acsomega.4c09030","volume":"10","author":"S Nakamura","year":"2024","unstructured":"Nakamura S, Asaba S, Tanaka M, Matsui T. Oral Administration of the Adiponectin Receptor 1 Agonistic Dipeptide Tyr-Pro Prevents Hyperglycemia in Spontaneously Diabetic Torii Rats. ACS Omega. 2024;10:1411\u20138. https:\/\/doi.org\/10.1021\/acsomega.4c09030.","journal-title":"ACS Omega"},{"key":"3577_CR86","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/1873-3468.14901","volume":"598","author":"A Coronell-Tovar","year":"2024","unstructured":"Coronell-Tovar A, Pardo JP, Rodr\u00edguez-Romero A, Sosa-Peinado A, V\u00e1squez-Bochm L, Cano-S\u00e1nchez P, et al. Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs. FEBS Lett. 2024;598:1811\u201338. https:\/\/doi.org\/10.1002\/1873-3468.14901.","journal-title":"FEBS Lett"},{"key":"3577_CR87","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-024-00965-1","volume":"20","author":"M Delibegovi\u0107","year":"2024","unstructured":"Delibegovi\u0107 M, Dall\u2019Angelo S, Dekeryte R. Protein tyrosine phosphatase 1B in metabolic diseases and drug development. Nat Rev Endocrinol. 2024;20:366\u201378. https:\/\/doi.org\/10.1038\/s41574-024-00965-1.","journal-title":"Nat Rev Endocrinol"},{"key":"3577_CR88","doi-asserted-by":"publisher","first-page":"115263","DOI":"10.1016\/j.bmc.2019.115263","volume":"28","author":"J Dowarah","year":"2020","unstructured":"Dowarah J, Singh VP. Anti-diabetic drugs recent approaches and advancements. Bioorg Med Chem. 2020;28:115263. https:\/\/doi.org\/10.1016\/j.bmc.2019.115263.","journal-title":"Bioorg Med Chem"},{"key":"3577_CR89","doi-asserted-by":"publisher","first-page":"e0240044","DOI":"10.1371\/journal.pone.0240044","volume":"15","author":"GS Kumar","year":"2020","unstructured":"Kumar GS, Page R, Peti W. The mode of action of the Protein tyrosine phosphatase 1B inhibitor Ertiprotafib. PLoS ONE. 2020;15:e0240044. https:\/\/doi.org\/10.1371\/journal.pone.0240044.","journal-title":"PLoS ONE"},{"key":"3577_CR90","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nprot.2006.77","volume":"1","author":"BY Feng","year":"2006","unstructured":"Feng BY, Shoichet BK. A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc. 2006;1:550\u20133. https:\/\/doi.org\/10.1038\/nprot.2006.77.","journal-title":"Nat Protoc"},{"key":"3577_CR91","doi-asserted-by":"publisher","first-page":"7076","DOI":"10.1021\/acs.jmedchem.5b01105","volume":"58","author":"JJ Irwin","year":"2015","unstructured":"Irwin JJ, Duan D, Torosyan H, Doak AK, Ziebart KT, Sterling T, et al. An Aggregation Advisor for Ligand Discovery. J Med Chem. 2015;58:7076\u201387. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01105.","journal-title":"J Med Chem"},{"key":"3577_CR92","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1002\/cpch.78","volume":"12","author":"SJ Allen","year":"2020","unstructured":"Allen SJ, Dower CM, Liu AX, Lumb KJ. Detection of Small-Molecule Aggregation with High-Throughput Microplate Biophysical Methods. Curr Protoc Chem Biol. 2020;12:e78. https:\/\/doi.org\/10.1002\/cpch.78.","journal-title":"Curr Protoc Chem Biol"},{"key":"3577_CR93","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ejmech.2017.12.064","volume":"144","author":"Y Du","year":"2018","unstructured":"Du Y, Zhang Y, Ling H, Li Q, Shen J. Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TC-PTP via modification interacting with C site. Eur J Med Chem. 2018;144:692\u2013700. https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.064.","journal-title":"Eur J Med Chem"},{"key":"3577_CR94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejmech.2016.04.014","volume":"118","author":"P Liu","year":"2016","unstructured":"Liu P, Du Y, Song L, Shen J, Li Q. Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity. Eur J Med Chem. 2016;118:27\u201333. https:\/\/doi.org\/10.1016\/j.ejmech.2016.04.014.","journal-title":"Eur J Med Chem"},{"key":"3577_CR95","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ejmech.2018.12.032","volume":"164","author":"F Xie","year":"2019","unstructured":"Xie F, Yang F, Liang Y, Li L, Xia Y, Jiang F, et al. Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors. Eur J Med Chem. 2019;164:408\u201322. https:\/\/doi.org\/10.1016\/j.ejmech.2018.12.032.","journal-title":"Eur J Med Chem"},{"key":"3577_CR96","doi-asserted-by":"publisher","first-page":"33224","DOI":"10.1021\/acsomega.4c04948","volume":"9","author":"ME Mendoza-Jasso","year":"2024","unstructured":"Mendoza-Jasso ME, P\u00e9rez-Villanueva J, Alvarado-Rodr\u00edguez JG, Gonz\u00e1lez-Andrade M, Cort\u00e9s-Ben\u00edtez F. 3-Benzylaminomethyl Lithocholic Acid Derivatives Exhibited Potent and Selective Uncompetitive Inhibitory Activity Against Protein Tyrosine Phosphatase 1B (PTP1B). ACS Omega. 2024;9:33224\u201338. https:\/\/doi.org\/10.1021\/acsomega.4c04948.","journal-title":"ACS Omega"},{"key":"3577_CR97","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/cbic.201600541","volume":"18","author":"MP Thomas","year":"2017","unstructured":"Thomas MP, Erneux C, Potter BV. SHIP2: Structure, Function and Inhibition. ChemBioChem. 2017;18:233\u201347. https:\/\/doi.org\/10.1002\/cbic.201600541.","journal-title":"ChemBioChem"},{"key":"3577_CR98","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1517\/14728222.2010.492780","volume":"14","author":"A Suwa","year":"2010","unstructured":"Suwa A, Kurama T, Shimokawa T. SHIP2 and its involvement in various diseases. Expert Opin Ther Targets. 2010;14:727\u201337. https:\/\/doi.org\/10.1517\/14728222.2010.492780.","journal-title":"Expert Opin Ther Targets"},{"key":"3577_CR99","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1210\/en.2007-0820","volume":"149","author":"S Kagawa","year":"2008","unstructured":"Kagawa S, Soeda Y, Ishihara H, Oya T, Sasahara M, Yaguchi S, et al. Impact of transgenic overexpression of SH2-containing inositol 5\u2019-phosphatase 2 on glucose metabolism and insulin signaling in mice. Endocrinology. 2008;149:642\u201350. https:\/\/doi.org\/10.1210\/en.2007-0820.","journal-title":"Endocrinology"},{"key":"3577_CR100","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.2337\/db06-1660","volume":"56","author":"R Grempler","year":"2007","unstructured":"Grempler R, Zibrova D, Schoelch C, van Marle A, Rippmann JF, Redemann N. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis. Diabetes. 2007;56:2235\u201341. https:\/\/doi.org\/10.2337\/db06-1660.","journal-title":"Diabetes"},{"key":"3577_CR101","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1476-5381.2009.00358.x","volume":"158","author":"A Suwa","year":"2009","unstructured":"Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, et al. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Br J Pharmacol. 2009;158:879\u201387. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00358.x.","journal-title":"Br J Pharmacol"},{"key":"3577_CR102","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1016\/j.bmcl.2015.09.034","volume":"25","author":"CM Russo","year":"2015","unstructured":"Russo CM, Adhikari AA, Wallach DR, Fernandes S, Balch AN, Kerr WG, et al. Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5\u2019-phosphatase (SHIP). Bioorg Med Chem Lett. 2015;25:5344\u20138. https:\/\/doi.org\/10.1016\/j.bmcl.2015.09.034.","journal-title":"Bioorg Med Chem Lett"},{"key":"3577_CR103","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ejmech.2013.01.014","volume":"62","author":"Y Ichihara","year":"2013","unstructured":"Ichihara Y, Fujimura R, Tsuneki H, Wada T, Okamoto K, Gouda H, et al. Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5\u2019-phosphatase 2 (SHIP2). Eur J Med Chem. 2013;62:649\u201360. https:\/\/doi.org\/10.1016\/j.ejmech.2013.01.014.","journal-title":"Eur J Med Chem"},{"key":"3577_CR104","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1096\/fj.201800529RR","volume":"33","author":"Z Polianskyte-Prause","year":"2019","unstructured":"Polianskyte-Prause Z, Tolvanen TA, Lindfors S, Dumont V, Van M, Wang H, et al. Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. FASEB J. 2019;33:2858\u201369. https:\/\/doi.org\/10.1096\/fj.201800529RR.","journal-title":"FASEB J"},{"key":"3577_CR105","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1021\/acsomega.9b02944","volume":"5","author":"MEA Berg","year":"2020","unstructured":"Berg MEA, Naams JB, Hautala LC, Tolvanen TA, Ahonen JP, Lehtonen S, W\u00e4h\u00e4l\u00e4 K. Novel Sulfonanilide Inhibitors of SHIP2 Enhance Glucose Uptake into Cultured Myotubes. ACS Omega. 2020;5:1430\u20138. https:\/\/doi.org\/10.1021\/acsomega.9b02944.","journal-title":"ACS Omega"},{"key":"3577_CR106","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1039\/d3md00360d","volume":"15","author":"PC Lim","year":"2023","unstructured":"Lim PC, Yap BK, Tay YJ, Hanapi NA, Yusof SR, Lee CY. Discovery of aurones bearing two amine functionalities as SHIP2 inhibitors with insulin-sensitizing effect in rat myotubes. RSC Med Chem. 2023;15:2179\u201395. https:\/\/doi.org\/10.1039\/d3md00360d.","journal-title":"RSC Med Chem"},{"key":"3577_CR107","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1021\/acs.jmedchem.0c01944","volume":"64","author":"H Whitfield","year":"2021","unstructured":"Whitfield H, Hemmings AM, Mills SJ, Baker K, White G, Rushworth S, et al. Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention. J Med Chem. 2021;64:3813\u201326. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01944.","journal-title":"J Med Chem"},{"key":"3577_CR108","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.7150\/ijbs.66314","volume":"18","author":"Z Polianskyte-Prause","year":"2022","unstructured":"Polianskyte-Prause Z, Tolvanen TA, Lindfors S, Kon K, Hautala LC, Wang H, et al. Ebselen enhances insulin sensitivity and decreases oxidative stress by inhibiting SHIP2 and protects from inflammation in diabetic mice. Int J Biol Sci. 2022;18:1852\u201364. https:\/\/doi.org\/10.7150\/ijbs.66314.","journal-title":"Int J Biol Sci"},{"key":"3577_CR109","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1463-1326.2012.01582.x","volume":"14","author":"CD Pereira","year":"2012","unstructured":"Pereira CD, Azevedo I, Monteiro R, Martins MJ. 11\u03b2-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:869\u201381. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01582.x.","journal-title":"Diabetes Obes Metab"},{"key":"3577_CR110","doi-asserted-by":"publisher","first-page":"37160","DOI":"10.1038\/srep37160","volume":"6","author":"K Peng","year":"2016","unstructured":"Peng K, Pan Y, Li J, Khan Z, Fan M, Yin H, et al. 11\u03b2-Hydroxysteroid Dehydrogenase Type 1(11\u03b2-HSD1) mediates insulin resistance through JNK activation in adipocytes. Sci Rep. 2016;6:37160. https:\/\/doi.org\/10.1038\/srep37160.","journal-title":"Sci Rep"},{"key":"3577_CR111","doi-asserted-by":"publisher","first-page":"154246","DOI":"10.1016\/j.metabol.2020","volume":"108","author":"S Gregory","year":"2020","unstructured":"Gregory S, Hill D, Grey B, Ketelbey W, Miller T, Muniz-Terrera G, Ritchie CW. 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis. Metabolism. 2020;108:154246. https:\/\/doi.org\/10.1016\/j.metabol.2020.","journal-title":"Metabolism"},{"key":"3577_CR112","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1124\/jpet.114.216556","volume":"351","author":"S Okazaki","year":"2014","unstructured":"Okazaki S, Takahashi T, Iwamura T, Nakaki J, Sekiya Y, Yagi M, et al. HIS-388, a novel orally active and long-acting 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models. J Pharmacol Exp Ther. 2014;351:181\u20139. https:\/\/doi.org\/10.1124\/jpet.114.216556.","journal-title":"J Pharmacol Exp Ther"},{"key":"3577_CR113","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejphar.2018.08.005","volume":"835","author":"SP Hong","year":"2018","unstructured":"Hong SP, Han D, Chang KH, Ahn SK. A novel highly potent and selective 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101. Eur J Pharmacol. 2018;835:169\u201378. https:\/\/doi.org\/10.1016\/j.ejphar.2018.08.005.","journal-title":"Eur J Pharmacol"},{"key":"3577_CR114","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1021\/acs.jmedchem.7b00211","volume":"60","author":"XY Ye","year":"2017","unstructured":"Ye XY, Chen SY, Wu S, Yoon DS, Wang H, Hong Z, et al. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3\u2019-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11\u03b2-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem. 2017;60:4932\u201348. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00211.","journal-title":"J Med Chem"},{"key":"3577_CR115","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1021\/acsmedchemlett.8b00307","volume":"9","author":"J Li","year":"2018","unstructured":"Li J, Kennedy LJ, Walker SJ, Wang H, Li JJ, Hong Z, et al. Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11\u03b2-Hydroxysteroid Dehydrogenase Type 1 (11\u03b2-HSD-1). ACS Med Chem Lett. 2018;9:1170\u20134. https:\/\/doi.org\/10.1021\/acsmedchemlett.8b00307.","journal-title":"ACS Med Chem Lett"},{"key":"3577_CR116","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1530\/JME-14-0268","volume":"55","author":"L Zhao","year":"2015","unstructured":"Zhao L, Pan Y, Peng K, Wang Z, Li J, Li D, et al. Inhibition of 11\u03b2-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice. J Mol Endocrinol. 2015;55:119\u201331. https:\/\/doi.org\/10.1530\/JME-14-0268.","journal-title":"J Mol Endocrinol"},{"key":"3577_CR117","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1016\/j.bmcl.2009.05.011","volume":"19","author":"M Siu","year":"2009","unstructured":"Siu M, Johnson TO, Wang Y, Nair SK, Taylor WD, Cripps SJ, et al. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorg Med Chem Lett. 2009;19:3493\u20137. https:\/\/doi.org\/10.1016\/j.bmcl.2009.05.011.","journal-title":"Bioorg Med Chem Lett"},{"key":"3577_CR118","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jsbmb.2007.03.023","volume":"104","author":"N Vicker","year":"2007","unstructured":"Vicker N, Su X, Ganeshapillai D, Smith A, Purohit A, Reed MJ, Potter BV. Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol. 2007;104:123\u20139. https:\/\/doi.org\/10.1016\/j.jsbmb.2007.03.023.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3577_CR119","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1474-9726.2010.00641.x","volume":"10","author":"AA Tomilov","year":"2011","unstructured":"Tomilov AA, Ramsey JJ, Hagopian K, Giorgio M, Kim KM, Lam A, et al. The Shc locus regulates insulin signaling and adiposity in mammals. Aging Cell. 2011;10:55\u201365. https:\/\/doi.org\/10.1111\/j.1474-9726.2010.00641.x.","journal-title":"Aging Cell"},{"key":"3577_CR120","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1038\/s41598-020-60290-1","volume":"10","author":"X Ding","year":"2020","unstructured":"Ding X, Iyer R, Novotny C, Metzger D, Zhou HH, Smith GI, et al. Inhibition of Grb14, a negative modulator of insulin signaling, improves glucose homeostasis without causing cardiac dysfunction. Sci Rep. 2020;10:3417. https:\/\/doi.org\/10.1038\/s41598-020-60290-1.","journal-title":"Sci Rep"},{"key":"3577_CR121","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.phrs.2018.09.024","volume":"137","author":"A Tomilov","year":"2018","unstructured":"Tomilov A, Allen S, Hui CK, Bettaieb A, Cortopassi G. Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. Pharmacol Res. 2018;137:89\u2013103. https:\/\/doi.org\/10.1016\/j.phrs.2018.09.024.","journal-title":"Pharmacol Res"},{"key":"3577_CR122","doi-asserted-by":"publisher","first-page":"110823","DOI":"10.1016\/j.biopha.2020.110823","volume":"132","author":"C Hui","year":"2020","unstructured":"Hui C, Tomilov A, Garcia C, Jiang X, Fash DM, Khdour OM, et al. Novel idebenone analogs block Shc\u2019s access to insulin receptor to improve insulin sensitivity. Biomed Pharmacother. 2020;132:110823. https:\/\/doi.org\/10.1016\/j.biopha.2020.110823.","journal-title":"Biomed Pharmacother"},{"key":"3577_CR123","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/febs.12080","volume":"280","author":"B Desbuquois","year":"2013","unstructured":"Desbuquois B, Carr\u00e9 N, Burnol AF. Regulation of insulin and type 1 insulin-like growth factor signaling and action by the Grb10\/14 and SH2B1\/B2 adaptor proteins. FEBS J. 2013;280:794\u2013816. https:\/\/doi.org\/10.1111\/febs.12080.","journal-title":"FEBS J"},{"key":"3577_CR124","doi-asserted-by":"publisher","first-page":"16901","DOI":"10.1038\/s41598-017-17122-6","volume":"7","author":"A Gondoin","year":"2017","unstructured":"Gondoin A, Hampe C, Eudes R, Fayolle C, Pierre-Eug\u00e8ne C, Miteva M, et al. Identification of insulin-sensitizing molecules acting by disrupting the interaction between the Insulin Receptor and Grb14. Sci Rep. 2017;7:16901. https:\/\/doi.org\/10.1038\/s41598-017-17122-6.","journal-title":"Sci Rep"},{"key":"3577_CR125","doi-asserted-by":"publisher","unstructured":"Ochi Y, Matsui T, Inoue K. Computational Screening and Experimental Validation of Inhibitor Targeting the Complex Formation of Grb14 and Insulin Receptor. Molecules 29:198. https:\/\/doi.org\/10.3390\/molecules29010198","DOI":"10.3390\/molecules29010198"},{"key":"3577_CR126","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s42003-021-02491-6","volume":"4","author":"S Furuzono","year":"2021","unstructured":"Furuzono S, Kubota T, Taura J, Konishi M, Naito A, Tsutsui M, et al. A xanthene derivative, DS20060511, attenuates glucose intolerance by inducing skeletal muscle-specific GLUT4 translocation in mice. Commun Biol. 2021;4:994. https:\/\/doi.org\/10.1038\/s42003-021-02491-6.","journal-title":"Commun Biol"},{"key":"3577_CR127","doi-asserted-by":"publisher","first-page":"130191","DOI":"10.1016\/j.bmcl.2025.130191","volume":"122","author":"M Meguro","year":"2025","unstructured":"Meguro M, Doi F, Soneda T, Furuzono S, Konishi M, Harada J, et al. Discovery of DS-1150b, a novel xanthene compound for activating GLUT4 translocation. Bioorg Med Chem Lett. 2025;122:130191. https:\/\/doi.org\/10.1016\/j.bmcl.2025.130191.","journal-title":"Bioorg Med Chem Lett"},{"key":"3577_CR128","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.chembiol.2023.06.012","volume":"30","author":"TC Yin","year":"2023","unstructured":"Yin TC, Van Vranken JG, Srivastava D, Mittal A, Buscaglia P, Moore AE, et al. Insulin sensitization by small molecules enhancing GLUT4 translocation. Cell Chem Biol. 2023;30:933\u201342. https:\/\/doi.org\/10.1016\/j.chembiol.2023.06.012. .e6.","journal-title":"Cell Chem Biol"},{"key":"3577_CR129","doi-asserted-by":"publisher","first-page":"1552176","DOI":"10.3389\/fphar.2025.1552176","volume":"16","author":"M Qin","year":"2025","unstructured":"Qin M, Yi X, Duan Z, Chang B, Li T. Recent insights on the impact of SWELL1 on metabolic syndromes. Front Pharmacol. 2025;16:1552176. https:\/\/doi.org\/10.3389\/fphar.2025.1552176.","journal-title":"Front Pharmacol"},{"key":"3577_CR130","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41467-022-28435-0","volume":"13","author":"SK Gunasekar","year":"2022","unstructured":"Gunasekar SK, Xie L, Kumar A, Hong J, Chheda PR, Kang C, et al. Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes. Nat Commun. 2022;13:784. https:\/\/doi.org\/10.1038\/s41467-022-28435-0.","journal-title":"Nat Commun"},{"key":"3577_CR131","doi-asserted-by":"publisher","first-page":"e42636","DOI":"10.7554\/eLife.42636","volume":"8","author":"DM Kern","year":"2019","unstructured":"Kern DM, Oh S, Hite RK, Brohawn SG. Cryo-EM structures of the DCPIB-inhibited volume-regulated anion channel LRRC8A in lipid nanodiscs. Elife. 2019;8:e42636. https:\/\/doi.org\/10.7554\/eLife.42636.","journal-title":"Elife"},{"key":"3577_CR132","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. https:\/\/doi.org\/10.1038\/srep42717.","journal-title":"Sci Rep"},{"key":"3577_CR133","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0090-9556(24)15347-0","volume":"28","author":"PJ Cox","year":"2000","unstructured":"Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, Cowley H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 2000;28:772\u201380.","journal-title":"Drug Metab Dispos"},{"key":"3577_CR134","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1074\/jbc.C117.819110","volume":"293","author":"N Krishnan","year":"2018","unstructured":"Krishnan N, Konidaris KF, Gasser G, Tonks NK. A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models. J Biol Chem. 2018;293:1517\u201325. https:\/\/doi.org\/10.1074\/jbc.C117.819110.","journal-title":"J Biol Chem"},{"key":"3577_CR135","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","volume":"79","author":"B Staels","year":"2023","unstructured":"Staels B, Butruille L, Francque S. Treating NASH by targeting peroxisome proliferator-activated receptors. J Hepatol. 2023;79:1302\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.004.","journal-title":"J Hepatol"},{"key":"3577_CR136","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1097\/MS9.0000000000001816","volume":"86","author":"R Taheripanah","year":"2024","unstructured":"Taheripanah R, Kazemi SN, Taheripanah A, Fereidoonjah S. A randomized controlled trial comparing pioglitazone and metformin prior to in vitro fertilization in polycystic ovary syndrome - associated infertile women: impact on pregnancy rates. Ann Med Surg (Lond). 2024;86:2696\u2013701. https:\/\/doi.org\/10.1097\/MS9.0000000000001816.","journal-title":"Ann Med Surg (Lond)"},{"key":"3577_CR137","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/jm0109513","volume":"45","author":"NH Hauel","year":"2002","unstructured":"Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45:1757\u201366. https:\/\/doi.org\/10.1021\/jm0109513.","journal-title":"J Med Chem"},{"key":"3577_CR138","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/pharmaceutics12111031","volume":"12","author":"M Markovic","year":"2020","unstructured":"Markovic M, Ben-Shabat S, Dahan A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics. 2020;12:1031. https:\/\/doi.org\/10.3390\/pharmaceutics12111031.","journal-title":"Pharmaceutics"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03577-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03577-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03577-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:41:42Z","timestamp":1792039302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03577-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":138,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3577"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03577-8","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}